Mineralys Therapeutics Stock
Mineralys Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jon Congleton
- Employees
- 76
- Market cap
- $1.8 B
- IPO
- 10/02/2023
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Radnor, Pennsylvania, USA. The company focuses on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its primary clinical-stage product candidate is lorundrostat, which is a proprietary,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Mineralys Therapeutics stock: price history
1D
-6.2%
1W
-13.1%
1M
-26.3%
6M
-33.6%
YTD
-44.1%
1Y
-52.8%
2Y
+45.6%
5Y
–
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~12% stronger price swings than usual
Ask the agents about Mineralys Therapeutics
Analyst assessment of Mineralys Therapeutics
PRICE TARGET LOW
US$29.00
CONSENSUS
US$29.00
MEDIAN
US$29.00
PRICE TARGET HIGH
US$29.00
0
STRONG BUY
7
BUY
1
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 12/10/2026
Mineralys Therapeutics stock metrics
P/E
-4.79
P/B
3.12
EV/EBITDA
-5.02
RETURN ON EQUITY
-43.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.18
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.8%
FLOAT SHARES
60,836,664
AVG. DAILY VOLUME (30D)
1,482,894
Insider transactions (SEC)
Congleton Jon
Slingsby Brian Taylor
Warren Eric
Warren Eric
Karydas Daphne
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -6.2%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Mineralys Therapeutics stock
What does Mineralys Therapeutics do?
Mineralys Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jon Congleton, the company employs around 76 people.
The IPO was on 10/02/2023; the stock trades on NASDAQ under the ticker MLYS.
What do analysts say about Mineralys Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 12/10/2026).
The average price target is US$29.00, ranging from US$29.00 to US$29.00, with a median of US$29.00.
This is an external assessment, not a statement by Market Jury.
When does Mineralys Therapeutics report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 12% stronger than usual.
Does Mineralys Therapeutics pay a dividend?
No, Mineralys Therapeutics currently does not pay a dividend.
Which stocks are comparable to Mineralys Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Mineralys Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Mineralys Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.